Ryosuke Tanino
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Proteomic analysis and genotyping of nontuberculosis mycobacteria to investigate effects of traditional Chinese medicines against pathogenesis
Open Date: 2013-04-01
Close Date: 2017-03-31
Articles (15)
The current standard postoperative adjuvant therapy for patients with epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC) includes chemotherapy, including microtubule inhibitors prior to the administration of osimertinib, an EGFR‐tyrosine kinase inhibitor (TKI). However, multidrug resistance following treatment with microtubule inhibitors has been reported, and the optimal sequence of drug administration for EGFR‐mutated NSCLC remains undefined. In this study, we investigated whether prior treatment with microtubule inhibitors induces acquired cross‐resistance to osimertinib in EGFR‐mutated NSCLC cells in vitro. To model acquired resistance, PC‐9 cells were exposed to vinorelbine or paclitaxel for 18 weeks—approximating the clinical duration of four adjuvant chemotherapy cycles—and subsequent drug sensitivity and signaling pathway alterations were assessed using cell viability assays, RNA sequencing, and immunoblotting. We found that two human NSCLC cell lines derived from PC‐9 exhibited reduced sensitivity to osimertinib after 18 weeks of in vitro treatment with tubulin inhibitors: vinorelbine (PC‐9/VNR) and paclitaxel (PC‐9/PTX). Furthermore, PC‐9/VNR and PC‐9/PTX cells showed activation of FZD7 and calcium/calmodulin‐dependent protein kinase II (CaMKII), along with increased sensitivity to the CaMKII inhibitor KN‐93, which exerted additive or synergistic effects. These findings suggest that CaMKII plays a critical role in EGFR‐TKI resistance. This study underscores the importance of optimizing the timing of EGFR‐TKI administration in the therapeutic sequence for EGFR‐mutated NSCLC.
Year:
2026
Year:
2025
Background: During bronchial lavage, the lumen can be viewed better by injecting physiological saline into the bronchus. This study aimed to investigate the effect of injecting physiological saline into the bronchus while directly observing the bronchial lumen with peripheral pulmonary lesions using an ultrathin bronchoscope. Methods: We evaluated changes in the depth of field and signal-to-noise ratio due to saline immersion in bronchoscopic images captured with line patterns. We injected physiological saline through the working channel into the bronchial lumen and directly observed the lesions (mainly in cases of suspected peripheral lung cancer) in 38 patients using white-light and narrow-band imaging. Ultrathin bronchoscopic findings and histopathological diagnoses were analyzed. Results: Saline immersion extended the range of subject distance within the depth of the field with an improved signal-to-noise ratio. Saline immersion elevated the signal-to-noise ratio and increased the highest signal-to-noise ratio in the white-light images from 3.12 dB to 3.77 dB (1.21-fold). Under narrow-band imaging, saline immersion also increased the highest signal-to-noise ratio from 5.18 dB to 6.44 dB (1.24-fold). We were able to directly observe the bronchial lumen of the peripheral lesions in 30/38 cases (78.9%). Three (60%) of the five squamous cell carcinomas were of the epithelial type, and 12 (92%) of the 13 adenocarcinomas, including peripheral pulmonary lesions, were of the subepithelial type, similar to central lesions. Conclusions: Injecting saline into the peripheral bronchus is useful for direct bronchoscopic evaluation of peripheral lesions.
Year:
2025
Year:
2025
Year:
2025
Hypoxia is a common feature of solid tumors. However, the impact of hypoxia on immune cells within tumor environments remains underexplored. Carbonic anhydrase 9 (CA9) is a hypoxia‐responsive tumor‐associated enzyme. We previously noted that regardless of human CA9 (hCA9) expression, hCA9‐expressing mouse renal cell carcinoma RENCA (RENCA/hCA9) presented as a “cold” tumor in syngeneic aged mice. This study delves into the mechanisms behind this observation. Gene microarray analyses showed that RENCA/hCA9 cells exhibited elevated mouse serpinB9, an inhibitor of granzyme B, relative to RENCA cells. Corroborating this, RENCA/hCA9 cells displayed heightened resistance to antigen‐specific cytotoxic T cells compared with RENCA cells. Notably, siRNA‐mediated serpinB9 knockdown reclaimed this sensitivity. In vivo tests showed that serpinB9 inhibitor administration slowed RENCA tumor growth, but this effect was reduced in RENCA/hCA9 tumors, even with adjunctive immune checkpoint blockade therapy. Further, inducing hypoxia or introducing the mouse CA9 gene upregulated serpinB9 expression, and siRNA‐mediated knockdown of the mouse CA9 gene inhibited the hypoxia‐induced induction of serpinB9 in the original RENCA cells. Supernatants from RENCA/hCA9 cultures had lower pH than those from RENCA, suggesting acidosis. This acidity enhanced serpinB9 expression and T cell apoptosis. Moreover, coculturing with RENCA/hCA9 cells more actively prompted T cell apoptosis than with RENCA cells. Collectively, these findings suggest hypoxia‐associated CA9 not only boosts serpinB9 in cancer cells but also synergistically intensifies T cell apoptosis via acidosis, characterizing RENCA/hCA9 tumors as “cold.”
Year:
2024
Background: Tyrosine kinase inhibitors (TKIs) inhibit receptor-mediated signals in cells. Axitinib is a TKI with high specificity for vascular endothelial growth factor receptors (VEGFRs). Aim: We determined whether axitinib could induce senescence in human cancer cells and be lysed by the senolytic drug ABT-263. Methods: Human lung and breast adenocarcinoma cell lines were used. These cells were cultured with axitinib or a multi-target TKI lenvatinib. The expression of β-galactosidase, VEGFRs, Ki-67, reactive oxygen species (ROS) of cancer cells, and their BrdU uptake were evaluated by flow cytometry. The mRNA expression of p21 and IL-8 was examined by quantitative PCR. The effects of TKIs on phosphorylation of Akt and Erk1/2, as downstream molecules of VEGFR signaling, were examined by immunoblot. The in vivo anti-cancer effect was examined using a xenograft mice model. Results: Axitinib, but not lenvatinib, induced cellular senescence (increased cell size and enhanced expression of β-galactosidase) in all adenocarcinoma cell lines. Axitinib-induced senescence was unrelated to the expression of VEGFRs on cancer cells. ROS were involved in axitinib-induced senescence. Axitinib-induced senescent lung adenocarcinoma A549 cells were drastically lysed by ABT-263. In A549-xenografted mice, combination therapy with axitinib and ABT-263 significantly suppressed tumor growth with the induction of apoptotic cancer cells.
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2021
Collaborators (3)
Tamio Okimoto
Junior Associate Professor
Shimane University Hospital
Hirotsugu Uemura
Professor
Kindai University
Yuichi Iida
Shimane University
Make your next move.
Prepare your application
Review drafts before you send them.